For Immediate Release: January 06, 2023 Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Leqembi is the second…
BarbaraJanuary 12, 2023
According to CMS plans announced Tuesday, the proposed CMS National Coverage Determination (NCD) would cover approved monoclonal antibodies targeting amyloid through coverage with evidence development (CED). To date, the only…
BarbaraJanuary 12, 2022
Five new on-demand webinars are available at no cost, and offer AMA PRA Category 1 Credits™. These webinars are focused at providing clinical staff tools to address the growing number…
BarbaraOctober 15, 2021
Aducanumab for Treatment of Alzheimer's Disease: Controversy & Patient Communications 1.5 CMA PRA Category 1 Credits This panel discussion among geriatric specialists will clarify controversial issues surrounding FDA's recent approval…
BarbaraAugust 23, 2021
The mobile app, awarded a Top 10 in 2017 by MedApps, has been updated to include guidance for caregivers, including the addition of a caregiver burden assessment instrument. The app…
BarbaraJune 25, 2021
The latest edition (June 2021) of the Alzheimer's Guidelines for Screening, Evaluation & Management of Alzheimer's Disease & Related Dementias is now available for clinicians.
BarbaraJune 25, 2021
Posters in English, Spanish, Arabic, Tagalog and Vietnamese are now available for free download for your exam and waiting rooms. Download here.
BarbaraJune 25, 2021
Q&A: What Physicians Ask About Diagnosing and Treating Dementia now available for AMA PRA Category 1 CreditsTM
BarbaraJune 25, 2019
Learn appropriate techniques for pain control and prescribing opioid medication and other pain management tools, specifically for older adult patients. AMA PRA Category 1 tm Credits Available. No cost webinar,…
BarbaraMarch 15, 2019
